Cancer immunoediting by the innate immune system in the absence of adaptive immunity
Open accessThe DOI matches its Crossref record; 58 of the 58 references it cites were found in a registry or an index.
Abstract
Cancer immunoediting is the process whereby immune cells protect against cancer formation by sculpting the immunogenicity of developing tumors. Although the full process depends on innate and adaptive immunity, it remains unclear whether innate immunity alone is capable of immunoediting. To determine whether the innate immune system can edit tumor cells in the absence of adaptive immunity, we compared the incidence and immunogenicity of 3'methylcholanthrene-induced sarcomas in syngeneic wild-type, RAG2(-/-), and RAG2(-/-)x γc(-/-) mice. We found that innate immune cells could manifest cancer immunoediting activity in the absence of adaptive immunity. This activity required natural killer (NK) cells and interferon γ (IFN-γ), which mediated the induction of M1 macrophages. M1 macrophages could be elicited by administration of CD40 agonists, thereby restoring editing activity in RAG2(-/-)x γc(-/-) mice. Our results suggest that in the absence of adaptive immunity, NK cell production of IFN-γ induces M1 macrophages, which act as important effectors during cancer immunoediting.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures









Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“In line with these findings, microbes may reverse the resistance to immunotherapy through reactivation of IFN-ɤ signaling pathways.”
From Gut Microbiome as a Potential Factor for Modulating Resistance to Cancer Immunotherapy (2020) · cites this paper as [91]
Experimental — accuracy not yet measuredIn the citing paper
“IFN-ɤ, an important cytokine involved in antitumor immunity, could upregulate MHC expression on tumor cells and M1 macrophages and facilitate the recognition and elimination of transformed cells (91, 92).”
From Gut Microbiome as a Potential Factor for Modulating Resistance to Cancer Immunotherapy (2020) · cites this paper as [91]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hallmarks of Cancer: The Next Generation
Hanahan, D., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.02.013 · Cited by 66,590 · cited 1×
“…for macrophages that is consistent with studies performed almost 40 yr ago, when it was shown that activated macrophages from infected mice (Hibbs et al., 1971) could kill syngeneic transformed murine embryonic fibroblasts, but not primary nontransformed murine embryonic fibroblasts (Hibbs…”
BackgroundTakahashi, K., & Yamanaka, S. (2006) · Cell · doi:10.1016/j.cell.2006.07.024 · Cited by 26,673 · cited 1×
“Using the 3 methylcholanthrene (MCA) model of sarcomagenesis, we previously found that the immune system in WT mice could edit tumors more effectively than the immune system in RAG2 / mice (which lack adaptive immunity; Shankaran et al., 2001; Takahashi and Yamanaka, 2006), but we did not assess whether tumors from RA…”
MethodCancer Immunoediting: Integrating Immunity’s Roles in Cancer Suppression and Promotion
Schreiber, R. D., Old, L. J., & Smyth, M. J. (2011) · Science · doi:10.1126/science.1203486 · Cited by 6,474
Self-citationMonocyte and macrophage heterogeneity
Gordon, S., & Taylor, P. R. (2005) · Nature Reviews Immunology · doi:10.1038/nri1733 · Cited by 5,190 · cited 4×
“M1 macrophages are activated classically via IFN- and function in the removal of intracellular pathogens (Gordon and Taylor, 2005).”
BackgroundResultInfluentialThe Three Es of Cancer Immunoediting
Dunn, G. P., Old, L. J., & Schreiber, R. D. (2004) · Annual Review of Immunology · doi:10.1146/annurev.immunol.22.012703.104803 · Cited by 3,072
Self-citationThe Immunobiology of Cancer Immunosurveillance and Immunoediting
Dunn, G. P., Old, L. J., & Schreiber, R. D. (2004) · Immunity · doi:10.1016/j.immuni.2004.07.017 · Cited by 3,032
Self-citationIFNγ and lymphocytes prevent primary tumour development and shape tumour immunogenicity
Shankaran, V., Ikeda, H., Bruce, A. T., White, J. M., Swanson, P. E., Old, L. J., & Schreiber, R. D. (2001) · Nature · doi:10.1038/35074122 · Cited by 2,896 · cited 13×
“Tumor induction by MCA was performed as previously described (Smyth et al., 2000; Shankaran et al., 2001).”
BackgroundMethodResultInfluentialSelf-citationAlternative Activation of Macrophages: An Immunologic Functional Perspective
Martinez, F. O., Helming, L., & Gordon, S. (2009) · Annual Review of Immunology · doi:10.1146/annurev.immunol.021908.132532 · Cited by 2,745 · cited 1×
“…characterized by quantitative PCR, using markers known to be associated with an M1-type phenotype (TNF and inducible nitric oxide synthase [iNOS]; Martinez et al., 2009) or with an M2-type phenotype (arginase and epithelial cadherin [eCAD]), growth arrest–specific gene 3 (Gas3; Ghassabeh et al.,…”
MethodDistinct role of macrophages in different tumor microenvironments
Lewis, C. E., & Pollard, J. W. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-4005 · Cited by 2,225 · cited 2×
“…that these macrophages were classically activated (Gordon and Taylor, 2005) M1 macrophages and performed immunophenotyping to detect the presence of tumor-associated M1 or M2 macrophages, known to have anti- or pro-tumor functions, respectively (Lewis and Pollard, 2006; Sica et al., 2008).”
BackgroundRAG-2-deficient mice lack mature lymphocytes owing to inability to initiate V(D)J rearrangement
Shinkai, Y. (1992) · Cell · doi:10.1016/0092-8674(92)90029-c · Cited by 2,150 · cited 1×
“Genotyping was performed using PCR (for IL-2R c, following The Jackson Laboratories protocol [http://jaxmice.jax.org/strain/003174.html]) or by Southern blot for RAG2 (Shinkai et al., 1992).”
MethodNatural Innate and Adaptive Immunity to Cancer
Vesely, M. D., Kershaw, M. H., Schreiber, R. D., & Smyth, M. J. (2011) · Annual Review of Immunology · doi:10.1146/annurev-immunol-031210-101324 · Cited by 2,101 · cited 2×
“…whereby the interaction between immune cells and tumor cells either eliminates the developing tumor, holds it in a state of growth dormancy, or generates a tumor cell repertoire that is capable of survival in immune-competent hosts (Shankaran et al., 2001; Dunn et al., 2004b; Vesely et al., 2011).”
BackgroundSelf-citationMajeti, R., Chao, M. P., Alizadeh, A. A., Pang, W. W., Jaiswal, S., Gibbs, K. D., van Rooijen, N., & Weissman, I. L. (2009) · Cell · doi:10.1016/j.cell.2009.05.045 · Cited by 1,752 · cited 1×
“Recent studies have also found that certain tumor cells can evade macrophage killing/phagocytosis by expressing high levels of CD47 (Jaiswal et al., 2009; Majeti et al., 2009) and/or low levels of calreticulin (Chao et al., 2010).”
BackgroundCD40 Agonists Alter Tumor Stroma and Show Efficacy Against Pancreatic Carcinoma in Mice and Humans
Beatty, G. L., Chiorean, E. G., Fishman, M. P., Saboury, B., Teitelbaum, U. R., Sun, W., Huhn, R. D., Song, W., Li, D., Sharp, L. L., et al. (2011) · Science · doi:10.1126/science.1198443 · Cited by 1,672 · cited 2×
“Notably, Beatty et al. (2011) investigated the role of tumoricidal macrophages activated in vivo with CD40 agonist treatments in the rejection of pancreatic ductal adenocarcinoma (PDA).”
BackgroundCD47 Is Upregulated on Circulating Hematopoietic Stem Cells and Leukemia Cells to Avoid Phagocytosis
Jaiswal, S., Jamieson, C. H. M., Pang, W. W., Park, C. Y., Chao, M. P., Majeti, R., Traver, D., van Rooijen, N., & Weissman, I. L. (2009) · Cell · doi:10.1016/j.cell.2009.05.046 · Cited by 1,581 · cited 1×
“This tumoricidal activity of macrophages required cell-cell contact and was induced largely by the cytokine IFN(Pace et al., 1983; Schreiber et al., 1983) in combination with additional signals such as LPS (Weinberg et al., 1978) or muramyl dipeptide (Kleinerman et al., 1983).”
BackgroundAdaptive immunity maintains occult cancer in an equilibrium state
Koebel, C. M., Vermi, W., Swann, J. B., Zerafa, N., Rodig, S. J., Old, L. J., Smyth, M. J., & Schreiber, R. D. (2007) · Nature · doi:10.1038/nature06309 · Cited by 1,436
Self-citationInflammation meets cancer, with NF-κB as the matchmaker
Ben-Neriah, Y., & Karin, M. (2011) · Nature Immunology · doi:10.1038/ni.2060 · Cited by 1,373 · cited 1×
“2012 Vol. 209 No. 10 1869-1882 www.jem.org/cgi/doi/10.1084/jem.20112738 1869 Immune cells can infiltrate a developing tumor mass and either promote or inhibit tumorigenesis (Balkwill and Coussens, 2004; Ben-Neriah and Karin, 2011; Schreiber et al., 2011).”
BackgroundInfluentialMacrophage polarization in tumour progression
Sica, A., Larghi, P., Mancino, A., Rubino, L., Porta, C., Totaro, M. G., Rimoldi, M., Biswas, S. K., Allavena, P., & Mantovani, A. (2008) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2008.03.004 · Cited by 1,241
Movahedi, K., Laoui, D., Gysemans, C., Baeten, M., Stangé, G., Van den Bossche, J., Mack, M., Pipeleers, D., In't Veld, P., De Baetselier, P., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-4672 · Cited by 1,239 · cited 2×
“M1-type and M2-type macrophages were gated as previously described (Movahedi et al., 2010; see Fig.”
MethodDefective lymphoid development in mice lacking expression of the common cytokine receptor γ chain
Cao, X., Shores, E. W., Hu-Li, J., Anver, M. R., Kelsail, B. L., Russell, S. M., Drago, J., Noguchi, M., Grinberg, A., Bloom, E. T., et al. (1995) · Immunity · doi:10.1016/1074-7613(95)90047-0 · Cited by 1,038 · cited 1×
“Having shown that c is important for the ability of innate immunity to control and edit MCA-induced sarcomas, we predicted that NK cells, dependent on c for development (Cao et al., 1995), would participate in this editing process in vivo.”
BackgroundSmyth, M. J., Dunn, G. P., & Schreiber, R. D. (2006) · Advances in Immunology · doi:10.1016/s0065-2776(06)90001-7 · Cited by 870 · cited 3×
“Several studies have revealed the contribution of adaptive and innate immunity in cancer immunoediting (Shankaran et al., 2001; Dunn et al., 2004a; Smyth et al., 2006; Dunn et al., 2005; Smyth et al., 2005; Street et al., 2004; Crowe et al., 2002; Takeda et al., 2002; Smyth et al. 2001), but it is not clear whether th…”
BackgroundSelf-citationNKG2D-deficient mice are defective in tumor surveillance in models of spontaneous malignancy
Guerra, N., Tan, Y. X., Joncker, N. T., Choy, A., Gallardo, F., Xiong, N., Knoblaugh, S., Cado, D., Greenberg, N. R., & Raulet, D. H. (2008) · Immunity · doi:10.1016/j.immuni.2008.02.016 · Cited by 850 · cited 1×
“These results confirm that cancer immunoediting of MCA-induced sarcomas is quite robust in WT mice and further validate that immune escape is an essential hallmark of cancer cells (Hanahan and Weinberg, 2011).”
ResultDifferential Tumor Surveillance by Natural Killer (Nk) and Nkt Cells
Smyth, M. J., Thia, K. Y. T., Street, S. E. A., Cretney, E., Trapani, J. A., Taniguchi, M., Kawano, T., Pelikan, S. B., Crowe, N. Y., & Godfrey, D. I. (2000) · The Journal of Experimental Medicine · doi:10.1084/jem.191.4.661 · Cited by 829 · cited 3×
“Tumor induction by MCA was performed as previously described (Smyth et al., 2000; Shankaran et al., 2001).”
BackgroundMethodSelf-citationChao, M. P., Jaiswal, S., Weissman-Tsukamoto, R., Alizadeh, A. A., Gentles, A. J., Volkmer, J., Weiskopf, K., Willingham, S. B., Raveh, T., Park, C. Y., et al. (2010) · Science Translational Medicine · doi:10.1126/scitranslmed.3001375 · Cited by 776
New aspects of natural-killer-cell surveillance and therapy of cancer
Smyth, M. J., Hayakawa, Y., Takeda, K., & Yagita, H. (2002) · Nature Reviews Cancer · doi:10.1038/nrc928 · Cited by 752 · cited 3×
“It has been shown that natural killer cells (NK; Smyth et al., 2002; Raulet and Guerra, 2009) and classically activated M1 macrophages (Sica et al.”
BackgroundSelf-citationBalkwill, F., & Coussens, L. M. (2004) · Nature · doi:10.1038/431405a · Cited by 627 · cited 2×
“2012 Vol. 209 No. 10 1869-1882 www.jem.org/cgi/doi/10.1084/jem.20112738 1869 Immune cells can infiltrate a developing tumor mass and either promote or inhibit tumorigenesis (Balkwill and Coussens, 2004; Ben-Neriah and Karin, 2011; Schreiber et al., 2011).”
BackgroundInfluentialCretney, E., Takeda, K., Yagita, H., Glaccum, M., Peschon, J. J., & Smyth, M. J. (2002) · The Journal of Immunology · doi:10.4049/jimmunol.168.3.1356 · Cited by 616 · cited 1×
“…al., 2006), natural killer group 2D (NKG2D; Guerra et al., 2008), DNAX accessory molecule-1 (Gilfillan et al., 2008; Iguchi-Manaka et al., 2008), perforin (van den Broek et al., 1996; Street et al., 2001), IFN- (Street et al., 2001), or TNF-related apoptosis-inducing ligand (Cretney et al., 2002).”
BackgroundSelf-citationA critical function for type I interferons in cancer immunoediting
Dunn, G. P., Bruce, A. T., Sheehan, K. C. F., Shankaran, V., Uppaluri, R., Bui, J. D., Diamond, M. S., Koebel, C. M., Arthur, C., White, J. M., et al. (2005) · Nature Immunology · doi:10.1038/ni1213 · Cited by 605
Self-citationPerforin and interferon-γ activities independently control tumor initiation, growth, and metastasis
Street, S. E. A., Cretney, E., & Smyth, M. J. (2001) · Blood · doi:10.1182/blood.v97.1.192 · Cited by 572 · cited 1×
“…al., 2006), natural killer group 2D (NKG2D; Guerra et al., 2008), DNAX accessory molecule-1 (Gilfillan et al., 2008; Iguchi-Manaka et al., 2008), perforin (van den Broek et al., 1996; Street et al., 2001), IFN- (Street et al., 2001), or TNF-related apoptosis-inducing ligand (Cretney et al., 2002).”
BackgroundSelf-citationImmune functions encoded by the natural killer gene complex
Yokoyama, W. M., & Plougastel, B. F. M. (2003) · Nature Reviews Immunology · doi:10.1038/nri1055 · Cited by 565 · cited 3×
“129/Sv strain (Yokoyama and Plougastel, 2003), new sets of MCA-induced sarcomas were generated using RAG2 / mice that had been bred by Taconic”
MethodInfluentialLethal influenza infection in the absence of the natural killer cell receptor gene Ncr1
Gazit, R., Gruda, R., Elboim, M., Arnon, T. I., Katz, G., Achdout, H., Hanna, J., Qimron, U., Landau, G., Greenbaum, E., et al. (2006) · Nature Immunology · doi:10.1038/ni1322 · Cited by 549 · cited 1×
“…by quantitative PCR, using markers known to be associated with an M1-type phenotype (TNF and inducible nitric oxide synthase [iNOS]; Martinez et al., 2009) or with an M2-type phenotype (arginase and epithelial cadherin [eCAD]), growth arrest–specific gene 3 (Gas3; Ghassabeh et al., 2006; Fig.”
MethodDecreased tumor surveillance in perforin-deficient mice.
van den Broek, M. E., Kägi, D., Ossendorp, F., Toes, R., Vamvakas, S., Lutz, W. K., Melief, C. J., Zinkernagel, R. M., & Hengartner, H. (1996) · The Journal of experimental medicine · doi:10.1084/jem.184.5.1781 · Cited by 512 · cited 1×
“…al., 2006), natural killer group 2D (NKG2D; Guerra et al., 2008), DNAX accessory molecule-1 (Gilfillan et al., 2008; Iguchi-Manaka et al., 2008), perforin (van den Broek et al., 1996; Street et al., 2001), IFN- (Street et al., 2001), or TNF-related apoptosis-inducing ligand (Cretney et al., 2002).”
BackgroundAntigenicity of Murine Skin Tumors Induced by Ultraviolet Light2
Kripke, M. L. (1974) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/53.5.1333 · Cited by 478 · cited 1×
“As described previously (Kripke, 1974; Boon and Kellermann, 1977; Flood et al., 1987; Shankaran et al., 2001; Dunn et al., 2005), we observed two divergent growth phenotypes among the transplanted sarcomas: a regressor phenotype, defined by a failure to form a mass of >9 mm in diameter in >50% of…”
BackgroundTakeda, K., Smyth, M. J., Cretney, E., Hayakawa, Y., Kayagaki, N., Yagita, H., & Okumura, K. (2002) · The Journal of Experimental Medicine · doi:10.1084/jem.20011171 · Cited by 465
Self-citationOncogenic stress sensed by the immune system: role of natural killer cell receptors
Raulet, D. H., & Guerra, N. (2009) · Nature Reviews Immunology · doi:10.1038/nri2604 · Cited by 404 · cited 2×
“…increased tumor incidences in mice lacking NK cells or molecules associated with NK cell recognition or effector function (Smyth et al., 2002, 2006; Raulet and Guerra, 2009), such as NKp46 (Gazit et al., 2006), natural killer group 2D (NKG2D; Guerra et al., 2008), DNAX accessory molecule-1…”
BackgroundImmunogenic Tumor Cell Death for Optimal Anticancer Therapy: The Calreticulin Exposure Pathway
Zitvogel, L., Kepp, O., Senovilla, L., Menger, L., Chaput, N., & Kroemer, G. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-2891 · Cited by 387 · cited 1×
“Other studies have implicated calreticulin exposure as a key initiator of innate immune responses to tumor cells, leading to antigen presentation and productive adaptive antitumor responses, and the blockade of these pathways could be a mechanism of tumor escape (Zitvogel et al., 2010).”
BackgroundNK cells and NKT cells collaborate in host protection from methylcholanthrene-induced fibrosarcoma
Smyth, M. J., Crowe, N. Y., & Godfrey, D. I. (2001) · International Immunology · doi:10.1093/intimm/13.4.459 · Cited by 379 · cited 2×
“Several studies have revealed the contribution of adaptive and innate immunity in cancer immunoediting (Shankaran et al., 2001; Dunn et al., 2004a; Smyth et al., 2006; Dunn et al., 2005; Smyth et al., 2005; Street et al., 2004; Crowe et al., 2002; Takeda et al., 2002; Smyth et al. 2001), but it is not clear whether th…”
BackgroundSelf-citationNK cells and NKT cells collaborate in host protection from methylcholanthrene-induced fibrosarcoma
Smyth, M. J. (2008) · International Immunology · doi:10.1093/intimm/dxn028 · Cited by 377
Self-citationGilfillan, S., Chan, C. J., Cella, M., Haynes, N. M., Rapaport, A. S., Boles, K. S., Andrews, D. M., Smyth, M. J., & Colonna, M. (2008) · The Journal of Experimental Medicine · doi:10.1084/jem.20081752 · Cited by 361
Self-citationCrowe, N. Y., Smyth, M. J., & Godfrey, D. I. (2002) · The Journal of Experimental Medicine · doi:10.1084/jem.20020092 · Cited by 352
Self-citationNKG2D function protects the host from tumor initiation
Smyth, M. J., Swann, J., Cretney, E., Zerafa, N., Yokoyama, W. M., & Hayakawa, Y. (2005) · The Journal of Experimental Medicine · doi:10.1084/jem.20050994 · Cited by 342 · cited 5×
“…tumor cell lines were harvested by trypsinization, washed 3 times with PBS, and injected at 106 cells subcutaneously into recipient C57BL/6, (129/Sv x C57BL/6) F1, RAG2 / , or RAG2 / x c / strain mice as previously described (Shankaran et al., 2001; Smyth et al., 2005; Bui et al., 2006).”
BackgroundMethodInfluentialSelf-citationCharacterization of the Effects of Endotoxin on Macrophage Tumor Cell Killing
Weinberg, J. B., Chapman, H. A., & Hibbs, J. B. (1978) · The Journal of Immunology · doi:10.4049/jimmunol.121.1.72 · Cited by 297 · cited 7×
“(Sigma-Aldrich) as previously described (Weinberg et al., 1978).”
BackgroundMethodInfluentialAccelerated tumor growth in mice deficient in DNAM-1 receptor
Iguchi-Manaka, A., Kai, H., Yamashita, Y., Shibata, K., Tahara-Hanaoka, S., Honda, S.-I., Yasui, T., Kikutani, H., Shibuya, K., & Shibuya, A. (2008) · The Journal of Experimental Medicine · doi:10.1084/jem.20081611 · Cited by 290
Innate Immune Surveillance of Spontaneous B Cell Lymphomas by Natural Killer Cells and γδ T Cells
Street, S. E. A., Hayakawa, Y., Zhan, Y., Lew, A. M., MacGregor, D., Jamieson, A. M., Diefenbach, A., Yagita, H., Godfrey, D. I., & Smyth, M. J. (2004) · The Journal of Experimental Medicine · doi:10.1084/jem.20031981 · Cited by 264 · cited 2×
“Several studies have revealed the contribution of adaptive and innate immunity in cancer immunoediting (Shankaran et al., 2001; Dunn et al., 2004a; Smyth et al., 2006; Dunn et al., 2005; Smyth et al., 2005; Street et al., 2004; Crowe et al., 2002; Takeda et al., 2002; Smyth et al. 2001), but it is not clear whether th…”
BackgroundSelf-citationSchreiber, R. D., Pace, J. L., Russell, S. W., Altman, A., & Katz, D. H. (1983) · The Journal of Immunology · doi:10.4049/jimmunol.131.2.826 · Cited by 235 · cited 1×
“This tumoricidal activity of macrophages required cell-cell contact and was induced largely by the cytokine IFN(Pace et al., 1983; Schreiber et al., 1983) in combination with additional signals such as LPS (Weinberg et al., 1978) or muramyl dipeptide (Kleinerman et al., 1983).”
BackgroundSelf-citationControl of Carcinogenesis: A Possible Role for the Activated Macrophage
Hibbs, J. B., Lambert, L. H., & Remington, J. S. (1972) · Science · doi:10.1126/science.177.4053.998 · Cited by 217
Macrophage activation: priming activity from a T-cell hybridoma is attributable to interferon-gamma.
Pace, J. L., Russell, S. W., Schreiber, R. D., Altman, A., & Katz, D. H. (1983) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.80.12.3782 · Cited by 184 · cited 1×
“This tumoricidal activity of macrophages required cell-cell contact and was induced largely by the cytokine IFN(Pace et al., 1983; Schreiber et al., 1983) in combination with additional signals such as LPS (Weinberg et al., 1978) or muramyl dipeptide (Kleinerman et al., 1983).”
BackgroundSelf-citationHibbs, J. B., Lambert, L. H., & Remington, J. S. (1971) · Journal of Infectious Diseases · doi:10.1093/infdis/124.6.587 · Cited by 183 · cited 1×
“…that is consistent with studies performed almost 40 yr ago, when it was shown that activated macrophages from infected mice (Hibbs et al., 1971) could kill syngeneic transformed murine embryonic fibroblasts, but not primary nontransformed murine embryonic fibroblasts (Hibbs et al., 1972) in vitro.”
ResultHassanzadeh Ghassabeh, G., De Baetselier, P., Brys, L., Noël, W., Van Ginderachter, J. A., Meerschaut, S., Beschin, A., Brombacher, F., & Raes, G. (2006) · Blood · doi:10.1182/blood-2005-04-1485 · Cited by 177
Wang, S.-C., Hong, J.-H., Hsueh, C., & Chiang, C.-S. (2012) · Laboratory Investigation · doi:10.1038/labinvest.2011.128 · Cited by 174 · cited 1×
“F4/80 marks all monocyte lineage cells, and CD68 marks mature tissue macrophages that are in tumors (Van Ginderachter et al., 2006; Wang et al., 2012).”
BackgroundBoon, T., & Kellermann, O. (1977) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.74.1.272 · Cited by 148 · cited 2×
“…administration of a CD40 agonist induces editing in RAG2 / x c / mice CD40 agonist administration in vivo has been shown to have antitumor properties (Buhtoiarov et al., 2005; Rakhmilevich et al., 2008) by activating TAMs to become tumoristatic through production of nitric oxide (Lum et al., 2006).”
BackgroundKleinerman, E. S., Erickson, K. L., Schroit, A. J., Fogler, W. E., & Fidler, I. J. (1983) · PubMed · Cited by 141
Buhtoiarov, I. N., Lum, H., Berke, G., Paulnock, D. M., Sondel, P. M., & Rakhmilevich, A. L. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.174.10.6013 · Cited by 125 · cited 2×
“…administration of a CD40 agonist induces editing in RAG2 / x c / mice CD40 agonist administration in vivo has been shown to have antitumor properties (Buhtoiarov et al., 2005; Rakhmilevich et al., 2008) by activating TAMs to become tumoristatic through production of nitric oxide (Lum et al., 2006).”
BackgroundVan Ginderachter, J. A., Meerschaut, S., Liu, Y., Brys, L., De Groeve, K., Hassanzadeh Ghassabeh, G., Raes, G., & De Baetselier, P. (2006) · Blood · doi:10.1182/blood-2005-09-3777 · Cited by 110 · cited 1×
“F4/80 marks all monocyte lineage cells, and CD68 marks mature tissue macrophages that are in tumors (Van Ginderachter et al., 2006; Wang et al., 2012).”
BackgroundIFN-Dependent Down-Regulation of the NKG2D Ligand H60 on Tumors
Bui, J. D., Carayannopoulos, L. N., Lanier, L. L., Yokoyama, W. M., & Schreiber, R. D. (2006) · The Journal of Immunology · doi:10.4049/jimmunol.176.2.905 · Cited by 101
Self-citationLum, H. D., Buhtoiarov, I. N., Schmidt, B. E., Berke, G., Paulnock, D. M., Sondel, P. M., & Rakhmilevich, A. L. (2006) · Immunology · doi:10.1111/j.1365-2567.2006.02366.x · Cited by 53 · cited 1×
“…administration of a CD40 agonist induces editing in RAG2 / x c / mice CD40 agonist administration in vivo has been shown to have antitumor properties (Buhtoiarov et al., 2005; Rakhmilevich et al., 2008) by activating TAMs to become tumoristatic through production of nitric oxide (Lum et al., 2006).”
BackgroundRakhmilevich, A. L., Buhtoiarov, I. N., Malkovský, M., & Sondel, P. M. (2008) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-007-0447-4 · Cited by 37 · cited 2×
“…administration of a CD40 agonist induces editing in RAG2 / x c / mice CD40 agonist administration in vivo has been shown to have antitumor properties (Buhtoiarov et al., 2005; Rakhmilevich et al., 2008) by activating TAMs to become tumoristatic through production of nitric oxide (Lum et al., 2006).”
BackgroundCancer Immunoediting of the NK Group 2D Ligand H60a
O’Sullivan, T. E., Dunn, G. P., LaCoursiere, D. Y., Schreiber, R. D., & Bui, J. D. (2011) · The Journal of Immunology · doi:10.4049/jimmunol.1100413 · Cited by 37
Self-citationProtective immunity to progressive tumors can be induced by antigen presented on regressor tumors.
Flood, P. M., Schreiber, H. W., & Ron, Y. (1987) · The Journal of Immunology · doi:10.4049/jimmunol.138.10.3573 · Cited by 19
Cited by
Roles of the immune system in cancer: From tumor initiation to metastatic progression
Gonzalez, H., Hagerling, C., & Werb, Z. (2018) · Genes & Development · doi:10.1101/gad.314617.118 · Cited by 2,111
“Moreover, CX3CR-1 patrolling monocytes inhibit metastatic progression through the recruitment of NK cells to the metastatic site, and then NK cell-derived IFN-γ reprograms macrophages into a tumoricidal effector macrophage state (O’Sullivan et al. 2012).”
Mittal, D., Gubin, M. M., Schreiber, R. D., & Smyth, M. J. (2014) · Current Opinion in Immunology · doi:10.1016/j.coi.2014.01.004 · Cited by 1,471
Self-citationRole of tumor microenvironment in tumorigenesis
Wang, M., Zhao, J., Zhang, L., Wei, F., Lian, Y., Wu, Y., Gong, Z., Zhang, S., Zhou, J., Cao, K., et al. (2017) · Journal of Cancer · doi:10.7150/jca.17648 · Cited by 1,404
NK cells and cancer: you can teach innate cells new tricks
Morvan, M. G., & Lanier, L. L. (2016) · Nature Reviews Cancer · doi:10.1038/nrc.2015.5 · Cited by 1,162
The Molecular Mechanism of Natural Killer Cells Function and Its Importance in Cancer Immunotherapy
Paul, S., & Lal, G. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.01124 · Cited by 825
Metadata
- Authors
- O’Sullivan, T., Saddawi-Konefka, R., Vermi, W., Koebel, C. M., Arthur, C., White, J. M., Uppaluri, R., Andrews, D. M., Ngiow, S. F., Teng, M. W. L., Smyth, M. J., Schreiber, R. D., & Bui, J. D.
- Affiliations
- University of California San Diego (US)
- Department of Pathology, University of California at San Diego, La Jolla, CA 92093 1
- University of Brescia (IT)
- Washington University in St. Louis (US)
- Center for Immunology, Department of Pathology and Immunology 3 and 4
- The University of Melbourne (AU)
- Corresponding author
- Bui, Jack D.
- ORCID
- Venue
- Journal of Experimental Medicine
- Publisher
- Rockefeller University Press
- Published
- 2012-08-27
- Volume
- 209
- Issue
- 10
- Pages
- 1869-1882
- ISSN
- 0022-1007 (ISSN-L)
- 1540-9538
- PMC
- PMC3457735
- OpenAlex
- W2144577255
- Cited by
- 348
- References
- 58
- Citations by year
- 2026: 11 · 2025: 8 · 2024: 24 · 2023: 31 · 2022: 22 · 2021: 30 · 2020: 29 · 2019: 25 · 2018: 32 · 2017: 30 · 2016: 27 · 2015: 23 · 2014: 21 · 2013: 29 · 2012: 6
- FWCI
- 11.05
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by-nc-sa
- Locations
- The Journal of Experimental Medicine (publishedVersion, cc-by-nc-sa)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-sa)
- PubMed Central (publishedVersion, cc-by-nc-sa)
- PubMed (publishedVersion)
- Digital Commons@Becker (Washington University School of Medicine) (submittedVersion)
- eScholarship (California Digital Library) (submittedVersion)
- eScholarship (California Digital Library) (submittedVersion, cc-by-nc-sa)
- Institutional Research Information System (Università degli Studi di Brescia) (submittedVersion, public-domain)
- Minerva Access (University of Melbourne) (submittedVersion, cc-by-nc-sa)
- Funders
- Cancer Research Institute
- Concern Foundation
- Hartwell Foundation (CA157885)
- Ludwig Institute for Cancer Research
- Cancer Research Coordinating Committee
- National Institutes of Health (CA157885)
- Medical Research Council
- National Health and Medical Research Council
- National Cancer Institute (CA 107527, CA128893, K08CA128893, K08CA090403, R01CA043059, R01CA157885, CA-43059, R37CA043059, R01CA107527, CA157885)
- National Center for Research Resources (C06RR012466)
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Immune cells in cancer
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Keywords
- cancer immunoediting, innate immunity, natural killer cells, interferon-gamma, M1 macrophages, CD40 agonist, Rag2 knockout mice, tumor immunogenicity, adaptive immunity
- MeSH terms
- Animals, Histocompatibility Antigens Class II, DNA-Binding Proteins, Immunity, Innate, Interferon-gamma, Killer Cells, Natural, Macrophages, Neoplasms, Phenotype, Sarcoma, Transplantation, Isogeneic, Mice, Knockout, CD40 Antigens, Genetic Predisposition to Disease, Cell Line, Tumor, Mice, Interleukin Receptor Common gamma Subunit, Adaptive Immunity, Immunomodulation
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.